Johnson & Johnson (JNJ) Aperçu de l'action
Johnson & Johnson, avec ses filiales, se consacre à la recherche et au développement, à la fabrication et à la vente d'une gamme de produits dans le domaine des soins de santé dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 0/6 |
| Performances passées | 3/6 |
| Santé financière | 4/6 |
| Dividendes | 5/6 |
JNJ Community Fair Values
Create NarrativeSee what 888 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Johnson & Johnson Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$270.24 |
| Plus haut sur 52 semaines | US$276.47 |
| Plus bas sur 52 semaines | US$173.33 |
| Bêta | 0.23 |
| Variation sur 1 mois | 2.60% |
| Variation sur 3 mois | 17.40% |
| Variation sur 1 an | 51.47% |
| Variation sur 3 ans | 64.49% |
| Variation sur 5 ans | 55.61% |
| Évolution depuis l'introduction en bourse | 43,138.47% |
Nouvelles et mises à jour récentes
Recent updates
Johnson & Johnson: Buy IMAAVY Label Expansion First And Continued CAPLYTA Sales Push
Summary Johnson & Johnson (JNJ) maintains a 'Buy' rating, driven by robust Q2 2026 sales growth and pipeline advancements. JNJ's top-performing drugs, DARZALEX and TREMFYA, fueled a 6.6% revenue increase to $25.3 billion, prompting raised full-year 2026 guidance. CAPLYTA's label expansion for schizophrenia relapse prevention and IMAAVY's potential first-mover status in wAIHA represent major growth catalysts. Risks include uncertain sustainability of high sales growth rates and regulatory outcomes for key pipeline assets. Read the full article on Seeking Alpha
JNJ: New Drug Cycle And Talc Settlement Progress Will Balance Policy Risks
Johnson & Johnson's analyst fair value estimate has been raised from $252.87 to $270.59, reflecting higher Street price targets tied to recent Q2 beats, updated guidance, progress on new medicines, and greater clarity around talc litigation exposure. Analyst Commentary Recent Street research on Johnson & Johnson points to a mix of enthusiasm around execution on new medicines and MedTech, alongside measured caution on policy and competitive pressures.
JNJ: Oncology Focus And New Medicines Will Drive Confidence Through 2026
Analysts raised the Johnson & Johnson fair value estimate to $305 from $265 after a series of price target increases tied to a recent quarterly beat, higher full year guidance, and growing confidence in the company's new medicines and projected revenue trajectory through 2026. Analyst Commentary Recent Street research around Johnson & Johnson has turned more constructive, with a cluster of upgrades and higher price targets following the latest quarterly results and revised guidance.
JNJ: Drug Pipeline Optimism Will Face Pressure From Medicare Pricing Rules
For Johnson & Johnson, the analyst price target has been revised higher. The updated fair value estimate has moved from about $181.77 to $212.24 as analysts factor in refreshed revenue growth assumptions, slightly adjusted discount and margin inputs, and a higher future P/E in light of recent research pointing to ongoing new drug momentum and broadly supportive earnings expectations.Johnson & Johnson (JNJ) Stock Could Be 7.3% Undervalued Based On Its Pharma And MedTech Focus
Johnson & Johnson (JNJ) is back in focus after recent share price weakness, with the stock down 2% over the past month and about 3% over the past 3 months, prompting fresh interest in its valuation. See our latest analysis for Johnson & Johnson. Despite the recent share price weakness over the past week and quarter, Johnson & Johnson’s year to date share price return of 10.15% and 1 year total shareholder return of 56.28% point to momentum that has been positive overall. If this kind of move...JNJ: Future Drug Cycle And Dividend Strength Will Balance Policy And Legal Risks
Analysts have raised the Johnson & Johnson price target to $265 from $252, reflecting increased confidence in the company’s new drug momentum and product cycle, while also considering ongoing policy and partnership risks highlighted in recent research. Analyst Commentary Recent Street research around Johnson & Johnson highlights a mix of enthusiasm about the company’s new drug pipeline and product cycle, alongside fresh policy questions and selected partnership headwinds that investors should factor into expectations for execution and valuation.JNJ: Future Drug Cycle Momentum Is Expected To Drive Returns
Analysts have nudged their price targets for Johnson & Johnson higher, with recent revisions clustering in the mid to high $260s and up to $280, as they point to strong new drug momentum and product cycle strength as key drivers supporting slightly higher revenue growth expectations and a rich future P/E framework. Analyst Commentary Recent research remains broadly constructive on Johnson & Johnson, with several bullish analysts citing product cycle momentum, new drug contributions, and a supportive P/E setup.JNJ: Future Drug Cycle And Legal Outcomes Are Expected To Shape Returns
Analysts have nudged their average price target on Johnson & Johnson slightly higher to about $253, citing stronger momentum from new drugs like Icotyde and Inlexzo, along with increased confidence in the pipeline highlighted in recent research updates. Analyst Commentary Recent research on Johnson & Johnson clusters around the same core themes you are seeing in price target moves, with most commentary tied to execution on new products, confidence in the pipeline, and how the company is positioned within healthcare more broadly.JNJ: Fair Outlook Balances Healthcare Demand With Legal And Portfolio Reshaping Risks
The analyst price target for Johnson & Johnson has been raised by about $11 to $252.42. Analysts point to stronger modeled revenue growth, higher projected profit margins, and a slightly richer future P/E multiple as key drivers of the update.JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience
Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks. Analyst Commentary Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely.JNJ: Fair Outlook Balances Legal Overhang With Core Healthcare Resilience
Analysts lifted the Johnson & Johnson fair value estimate by about $3.79 to $241.08, citing higher assumed revenue growth, slightly adjusted profit margin expectations, and a modestly higher future P/E multiple supported by recent upward price target revisions across the Street. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more constructive, with a series of higher price targets clustered above the latest fair value estimate.Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?JNJ: Pharma Pipeline Momentum Balanced By Talc And Orthopedics Uncertainty
Analysts have nudged their average price target on Johnson & Johnson higher by about $5 per share, reflecting updated views on the company’s pharmaceutical pipeline, including stronger expectations around Tremfya and other near term therapies such as Tecvayli, Inlexzo and Darzalex treatment duration. Analyst Commentary Recent Street research on Johnson & Johnson has centered on how the pharma pipeline feeds into valuation, with analysts updating targets around specific products rather than broad macro calls.JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk
The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.Rendement pour les actionnaires
| JNJ | US Pharmaceuticals | US Marché | |
|---|---|---|---|
| 7D | 3.0% | 5.4% | -1.2% |
| 1Y | 51.5% | 58.5% | 18.3% |
Rendement vs Industrie: JNJ a sous-performé le secteur US Pharmaceuticals qui a rapporté 58.5 % au cours de l'année écoulée.
Rendement vs marché: JNJ a dépassé le marché US qui a rapporté 18.3 % au cours de l'année écoulée.
Volatilité des prix
| JNJ volatility | |
|---|---|
| JNJ Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: JNJ n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de JNJ ( 4% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1886 | 138,200 | Joaquin Duato | www.jnj.com |
Johnson & Johnson, avec ses filiales, se consacre à la recherche et au développement, à la fabrication et à la vente d'une gamme de produits dans le domaine des soins de santé dans le monde entier. Elle opère dans deux segments, la médecine innovante et les technologies médicales. Le segment de la médecine innovante propose des produits pour divers domaines thérapeutiques, tels que l'oncologie, l'immunologie, les neurosciences, l'hypertension pulmonaire, les maladies infectieuses et les maladies cardiovasculaires et métaboliques, distribués par des détaillants, des grossistes, des distributeurs, des hôpitaux et des professionnels de la santé sur prescription médicale.
Johnson & Johnson Résumé des fondamentaux
| JNJ statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$651.25b |
| Bénéfices(TTM) | US$21.04b |
| Recettes(TTM) | US$97.93b |
Le site JNJ est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| JNJ compte de résultat (TTM) | |
|---|---|
| Recettes | US$97.93b |
| Coût des recettes | US$31.20b |
| Marge brute | US$66.73b |
| Autres dépenses | US$45.69b |
| Les revenus | US$21.04b |
Derniers bénéfices déclarés
Jun 28, 2026
Prochaine date de publication des résultats
Oct 13, 2026
| Résultat par action (EPS) | 8.73 |
| Marge brute | 68.14% |
| Marge bénéficiaire nette | 21.48% |
| Ratio dettes/capitaux propres | 57.7% |
Quelles ont été les performances à long terme de JNJ?
Voir les performances historiques et les comparaisonsDividendes
Le site JNJ verse-t-il des dividendes fiables ?
Voir JNJ l'historique des dividendes et les indices de référence| Johnson & Johnson dates des dividendes | |
|---|---|
| Date ex-dividende | Aug 25 2026 |
| Date de paiement du dividende | Sep 08 2026 |
| Jours jusqu'au dividende Ex | 1 day |
| Jours jusqu'à la date de paiement du dividende | 15 days |
Le site JNJ verse-t-il des dividendes fiables ?
Voir JNJ l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/24 04:30 |
| Cours de l'action en fin de journée | 2026/08/21 00:00 |
| Les revenus | 2026/06/28 |
| Revenus annuels | 2025/12/28 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Johnson & Johnson est couverte par 53 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Lee Hambright | Bernstein |